Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Recruiting 5 Active not recruiting 4 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

pembrolizumab 75 Carboplatin 61 Cyclophosphamide 58 Nivolumab 50 Paclitaxel 47 Gemcitabine 44 Cisplatin 43 Dexamethasone 41 Radiotherapy 35 Rituximab 32 Capecitabine 31 Docetaxel 29 Bevacizumab 29 fludarabine 27 atezolizumab 26 Cytarabine 26 avelumab 24 Trastuzumab 23 Oxaliplatin 23 Lenalidomide 23 Cetuximab 23 venetoclax 22 Fluorouracil 22 Azacitidine 22 Temozolomide 21 Ipilimumab 21 130-nm albumin-bound paclitaxel 21 fludarabine phosphate 20 Filgrastim 20 Bortezomib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × glofitamab × Clear all

NCT05896163 2026-05-06

MAPtivate-6

Pfizer

Phase 1/2 Terminated

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡